Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is viewed favorably because its lead asset, Ampligen, is being tested in combination with checkpoint blockade therapies at multiple major U.S. cancer research centers, creating several shots on goal across oncology indications. The company’s investment case is strengthened by positive initial and recent trial data, with additional clinical readouts expected over the next year, which could further validate efficacy, improve tumor response and survival metrics, and serve as meaningful catalysts. Despite development timelines of roughly 2 years to 3 years and substantial execution risk, the potential for billion-dollar market opportunities and an attractive NPV-based valuation supports an optimistic fundamental outlook.

Bears say

AIM ImmunoTech is a clinical-stage biotech with minimal revenue, and its fundamentals remain weak because it has not yet proven it can convert its pipeline into commercial cash flow. In Q2 2026, it posted a $7 million net loss, or $(0.43) per share, and in Q1 2026 it lost $3.0 million, or $(0.69) per share, underscoring persistent losses despite no guidance and limited operating visibility. The outlook is negative because the company still faces balance sheet and liquidity risk, plus major binary uncertainties around clinical safety, efficacy, regulatory approval, reimbursement, and commercialization.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Oct 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.